top of page

ImmunoGen and Merck collaborate for ovarian cancer trial

ImmunoGen and Merck (known as MSD outside the US and Canada) are to assess ImmunoGen’s mirvetuximab soravtansine in combination with Merck’s Keytruda (pembrolizumab) for the treatment of patients with FRα-positive ovarian cancer.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page